Biopharma Can Reduce the Cost of Bringing A Treatment to Market by More Than US$1 Billion, According to Accenture Report
Accenture plc Class A Ordinary Shares (Ireland) (ACN)
Last accenture plc class a ordinary shares (ireland) earnings: 3/19 06:44 am
Check Earnings Report
US:NYSE Investor Relations:
investor.accenture.com
Company Research
Source: Business Wire
Savings could be passed on to patients to improve affordability and access NEW YORK--(BUSINESS WIRE)--A new report from Accenture (NYSE: ACN) identifies three steps biopharmaceutical organizations could take to reduce the average cost of discovering and developing a treatment by more than US$1 billion. Furthermore, it could potentially create additional future revenue opportunities of up to US$450 million per treatment.The report, titled “From Billions to Millions: Faster innovation. Greater R&D productivity” notes that the cost of bringing a successful treatment to market is between US$2.6 billion and $6.7 billion, depending on therapeutic area, treatment modality and disease complexity. However, the combined use of “New Science” (which is a unique combination of the best in science and health technology that address significant unmet patient needs); digital and data-led research; and faster, smarter development could improve R&D productivity including lowering the cost of bringin
Show less
Read more
Impact Snapshot
Event Time:
ACN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACN alerts
High impacting Accenture plc Class A Ordinary Shares (Ireland) news events
Weekly update
A roundup of the hottest topics
ACN
News
- Accenture (ACN) Stock Sinks As Market Gains: Here's Why [Yahoo! Finance]Yahoo! Finance
- Global Digital Workplace Market Analysis 2024-2028 by Component, Application and Region - Drivers, Challenges, Trends, Key Players, Customer Landscape [Yahoo! Finance]Yahoo! Finance
- California is testing new generative AI tools. Here's what to know [Financial Post (Toronto, Ontario, Canada)]Financial Post
- California is testing new generative AI tools. Here's what to know [Yahoo! Finance Canada]Yahoo! Finance Canada
- California is testing new generative AI tools. Here's what to know [Yahoo! Finance]Yahoo! Finance
ACN
Earnings
- 3/21/24 - Beat
ACN
Sec Filings
- 5/6/24 - Form 4
- 5/6/24 - Form 4
- 5/6/24 - Form 4
- ACN's page on the SEC website